Genelux (NASDAQ:GNLX) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Posted by Brenda Bartman on Aug 13th, 2026

Genelux (NASDAQ:GNLX – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01), Zacks reports.

Genelux Stock Down 0.9%

Shares of NASDAQ GNLX traded down $0.03 on Thursday, reaching $2.67. 199,188 shares of the company’s stock traded hands, compared to its average volume of 223,060. The business’s 50 day simple moving average is $2.90 and its two-hundred day simple moving average is $2.78. Genelux has a 12 month low of $2.29 and a 12 month high of $8.53. The company has a market cap of $119.95 million, a price-to-earnings ratio of -3.15 and a beta of 0.60.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a research report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Genelux presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

View Our Latest Research Report on Genelux

Insider Buying and Selling

In other news, Director John Thomas sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $2.98, for a total value of $29,800.00. Following the sale, the director directly owned 472,784 shares of the company’s stock, valued at $1,408,896.32. The trade was a 2.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director John W. Smither sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $2.91, for a total value of $34,920.00. Following the completion of the sale, the director owned 91,403 shares in the company, valued at $265,982.73. The trade was a 11.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 25,868 shares of company stock worth $76,120. Insiders own 7.50% of the company’s stock.

Hedge Funds Weigh In On Genelux

Several institutional investors and hedge funds have recently modified their holdings of the stock. ExodusPoint Capital Management LP bought a new position in Genelux in the 4th quarter worth about $238,000. OMERS ADMINISTRATION Corp bought a new stake in Genelux during the 4th quarter valued at about $239,000. Hudson Bay Capital Management LP purchased a new position in Genelux in the fourth quarter worth about $165,000. Susquehanna International Group LLP raised its holdings in Genelux by 140.3% in the third quarter. Susquehanna International Group LLP now owns 52,383 shares of the company’s stock worth $220,000 after buying an additional 30,583 shares during the last quarter. Finally, Creative Planning lifted its stake in shares of Genelux by 4.7% in the third quarter. Creative Planning now owns 46,108 shares of the company’s stock worth $194,000 after buying an additional 2,084 shares in the last quarter. 37.33% of the stock is currently owned by institutional investors.

About Genelux

(Get Free Report)

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.